Surrozen Past Earnings Performance

Past criteria checks 0/6

Surrozen's earnings have been declining at an average annual rate of -4%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 52.6% per year.

Key information

-4.0%

Earnings growth rate

26.3%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	52.6%
Return on equity	-784.2%
Net Margin	-444.4%
Last Earnings Update	30 Sep 2024

Recent past performance updates

No updates

Recent updates

Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation

Aug 21

Revenue & Expenses Breakdown

How Surrozen makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:SRZN Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	10	-44	15	0
30 Jun 24	0	-53	15	-4
31 Mar 24	0	-38	14	0
31 Dec 23	0	-43	16	0
30 Sep 23	13	-35	17	0
30 Jun 23	13	-38	19	14
31 Mar 23	13	-42	20	0
31 Dec 22	13	-36	20	0
30 Sep 22	0	-50	19	0
30 Jun 22	0	-51	17	-19
31 Mar 22	0	-50	15	-9
31 Dec 21	0	-55	14	0
30 Sep 21	0	-51	12	9
30 Jun 21	0	-45	11	34
31 Mar 21	0	-39	10	30
31 Dec 20	0	-33	7	26

Quality Earnings: SRZN is currently unprofitable.

Growing Profit Margin: SRZN is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SRZN is unprofitable, and losses have increased over the past 5 years at a rate of 4% per year.

Accelerating Growth: Unable to compare SRZN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SRZN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).

Return on Equity

High ROE: SRZN has a negative Return on Equity (-784.15%), as it is currently unprofitable.

Surrozen Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

New major risk - Financial position

Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation

Price target decreased by 45% to US$33.00

Surrozen, Inc. Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Surrozen, Inc., Annual General Meeting, Jun 05, 2024

Surrozen, Inc. announced delayed annual 10-K filing

Surrozen Provides Update on the Phase 1A Clinical Trial of SZN-043 in Healthy Volunteers and Patients with Cirrhosis

Surrozen, Inc. announced that it expects to receive $17.549999 million in funding from The Column Group, LLC, Ra Capital Management, Inc.

Surrozen, Inc. Appoints Charles Williams to the Concurrent Position of Chief Operating Officer

Surrozen, Inc. Provides Corporate Update on Clinical Programs

Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Surrozen, Inc. Expects to Initiate A Phase 1a Clinical Trials for SZN-043 and SZN-1326 in Moderate to Severe Alcoholic Hepatitis

New minor risk - Share price stability

Surrozen, Inc. Announces Management Changes

Nasdaq Grants Surrozen Additional 180 Calendar Day Period to Regain Compliance with the Minimum Bid Price Per Share Requirement for Continued Listing

Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?

Here's Why Surrozen (NASDAQ:SRZN) Must Use Its Cash Wisely

Surrozen Receives A Written Notice from Nasdaq Regarding Minimum Bid Requirement

Surrozen, Inc. (NasdaqCM:SRZN) announces an Equity Buyback for 1,310,496 shares, for $2.7 million.

Surrozen, Inc. Updates SZN-1326, SZN-043 and SZN-413 for Vascular-Associated Retinopathies, Including Diabetic Retinopathy and Diabetic Macular Edema

Price target decreased to US$12.50

Surrozen stock rises ~13% premarket on licensing deal with Boehringer Ingelheim

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of Szn-413 in Preclinical Models of Diabetic Retinopathy

Surrozen GAAP EPS of -$0.40 beats by $0.06

Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

Price target increased to US$19.50

Surrozen, Inc. Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Surrozen, Inc. Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

Surrozen, Inc. Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy At the Association for Research in Vision and Ophthalmology Annual Meeting

Surrozen CEO Craig Parker - Biotechs Can Never Be Too Well Capitalized (Video)

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies